The estimated Net Worth of Young Kwon is at least $19.2 Million dollars as of 23 August 2024. Young Kwon owns over 60,000 units of Momenta Pharmaceuticals stock worth over $12,670,824 and over the last 7 years Young sold MNTA stock worth over $6,550,717.
Young has made over 37 trades of the Momenta Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently Young sold 60,000 units of MNTA stock worth $1,095,600 on 23 August 2024.
The largest trade Young's ever made was buying 100,000 units of Momenta Pharmaceuticals stock on 25 October 2021 worth over $100,000. On average, Young trades about 9,854 units every 48 days since 2018. As of 23 August 2024 Young still owns at least 241,441 units of Momenta Pharmaceuticals stock.
You can see the complete history of Young Kwon stock trades at the bottom of the page.
Young's mailing address filed with the SEC is C/O ADMA BIOLOGICS, INC., 465 STATE ROUTE 17, RAMSEY, NJ, 07446.
Over the last 20 years, insiders at Momenta Pharmaceuticals have traded over $110,027,424 worth of Momenta Pharmaceuticals stock and bought 827,300 units worth $5,505,611 . The most active insiders traders include Christoph H Westphal, Craig A Wheeler und Peter Barrett. On average, Momenta Pharmaceuticals executives and independent directors trade stock every 6 days with the average trade being worth of $448,442. The most recent stock trade was executed by Ian Fier on 20 August 2020, trading 1,808 units of MNTA stock currently worth $94,323.
Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.
Momenta Pharmaceuticals executives and other stock owners filed with the SEC include: